Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP Amy Beth Vanduyn sold 604 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $26.98, for a total transaction of $16,295.92. Following the completion of the transaction, the senior vice president now owns 115,029 shares of the company’s stock, valued at approximately $3,103,482.42. The trade was a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amy Beth Vanduyn also recently made the following trade(s):
- On Monday, January 6th, Amy Beth Vanduyn sold 1,311 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $34,885.71.
- On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The shares were sold at an average price of $20.93, for a total value of $532,605.71.
Phreesia Trading Up 1.6 %
NYSE:PHR opened at $27.24 on Friday. The stock has a 50-day simple moving average of $23.42 and a two-hundred day simple moving average of $22.77. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $29.16.
Analyst Ratings Changes
PHR has been the topic of several research analyst reports. Truist Financial upped their target price on shares of Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Robert W. Baird lowered their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Citigroup lifted their target price on shares of Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. JMP Securities reissued a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a report on Tuesday, December 10th. Finally, Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia has an average rating of “Buy” and a consensus target price of $31.00.
Read Our Latest Stock Analysis on Phreesia
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Wesbanco Bank Inc. raised its holdings in Phreesia by 76.9% during the fourth quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock valued at $1,157,000 after acquiring an additional 20,000 shares during the period. Franklin Resources Inc. raised its stake in Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock valued at $31,495,000 after purchasing an additional 42,973 shares during the period. Geode Capital Management LLC raised its stake in Phreesia by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,245,797 shares of the company’s stock valued at $28,397,000 after purchasing an additional 55,934 shares during the period. M&T Bank Corp lifted its holdings in Phreesia by 4.6% in the 3rd quarter. M&T Bank Corp now owns 35,127 shares of the company’s stock worth $801,000 after purchasing an additional 1,535 shares in the last quarter. Finally, Barclays PLC grew its holdings in Phreesia by 83.6% during the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after buying an additional 43,225 shares in the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
- Five stocks we like better than Phreesia
- Canada Bond Market Holiday: How to Invest and Trade
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- What is the FTSE 100 index?
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- 3 Warren Buffett Stocks to Buy Now
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.